EVGN (Evogene Ltd) רווח למניה לשנה מתגלגלת

Evogene Ltd. is building a powerful defensive moat through its computational biology IT platform, operating within the strict regulatory framework of the EPA. The rolling annual EPS change metric visualizes this process, where the value of 59.10 expresses the metric level. Algorithm patents and access to genomic data block competitors, while international contracts in the US mitigate Israel's geopolitical risks.
פילוחי מדדים פיננסיים ומדדי שוק עבור Evogene Ltd (EVGN)

Defensive assets are selected based on the criterion of stable net profit growth, which for Evogene Ltd. (EVGN) is driven by the technological advantage of its AI platform amid strict EPA controls. An analysis of the historical EPS YoY TTM delta allows for an assessment of the earnings per share growth rate over the last twelve months, neutralizing market noise and confirming the fundamental resilience of the business.